Skip to main content

Table 1 Cohort characteristics

From: Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study

  Cases
(n = 148)
Controls
(n = 32)
Mean age at delivery in years (SD) 32.3 (3.8) 32.0 (4.4)
Median disease duration at delivery in years (range) 8.0 (0.7 to 29.7) -
Number of nulliparous women, n (%) 70/147 (47.6) 14/32 (43.8%)
Mean gestational age at delivery, weeks (range) 39.3 (31.4 to 42.1) 40.4 (34.0 to 42.0)
Breastfeeding (six weeks postpartum), n (%) 62/148 (41.9) 27/32 (84.4)
Anti-CCP positive, n (%) 93/147 (63.3) -
Rheumatoid Factor (IgM) positive, n (%) 108/148 (73.0) -
Erosive disease, n (%) 43/147 (70.7)  
DAS28-CRP3 >3.2 in first trimester, n (%) 75 (61.5) -
Classification of disease activity during pregnancy   
   good response/moderate response 37/75 (49.3) -
   no response 38/75 (50.7) -
Classification of disease activity during postpartum period
(early flare)
  
   severe deterioration/moderate deterioration (n, %) 35/141* (24.8) -
   no deterioration (n, %) 106/141* (75.2) -
Classification of disease activity during postpartum period
(late flare)
  
   severe deterioration/moderate deterioration (n, %) 29/141* (20.6) -
   no deterioration (n, %) 112/141* (79.4) -
Median number of DMARDs (incl prednisone)
prior to conceive (min-max)
2 (0-7) -
No DMARD** use prior to conceive, n (%) 7/147 (4.8)  
Use of methotrexate prior to conceive, n (%) 75/147 (51.0) -
  1. *n = 7 cases are missing, since a small proportion of DAS scores are missing.
  2. ** DMARDs: disease modifying anti-rheumatic drugs.